-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] In recent years, with the introduction of favorable policies, the market space of traditional Chinese medicine has been further opened up.
It is predicted that the traditional Chinese medicine market will exceed 1 trillion yuan in 2024, and the market prospect is very impressive
.
Since March 2022, many traditional Chinese medicine companies have also been investigated by institutions
.
For example, Zhenbao Island stated in its investor relations activity record sheet released on March 29 that the company accepted four institutional surveys on March 25, 2022, with the types of institutions being insurance companies, fund companies, and securities companies
.
Kunpharm Group stated in the investor relations activity record sheet released on March 22 that the company received investigations from 22 institutions on March 21, 2022.
The types of institutions are insurance companies, others, fund companies, securities companies, and sunshine private equity institutions.
.
On March 17, Watson Pharmaceuticals released an investor relations activity record sheet, stating that the company received investigations from 6 institutional units on March 17, 2022.
The types of institutions are others, fund companies, securities companies, and sunshine private equity institutions
.
During the survey, issues such as the distribution of innovative Chinese medicines have become one of the topics that institutions are more concerned about
.
So what is the layout and progress of the above-mentioned companies under investigation in innovative traditional Chinese medicine? Among them, Zhenbao Island said in response to the agency's question on "the future layout of innovative traditional Chinese medicine drugs? How will it affect the company?" The company is deploying innovative traditional Chinese medicine products, and it will take time to launch innovative drugs according to the characteristics of different varieties
.
At present, some varieties are immediately undergoing Phase II clinical trials, while others are undergoing pharmaceutical research.
It is expected that they will be approved by the end of next year, and others have already been approved
.
The supplement of other traditional Chinese medicine varieties is also constantly introducing products with clinical and market value, and constantly supplementing short-term products and several large varieties.
Sales are expected this year
.
The research and development and introduction of innovative traditional Chinese medicine drugs will further enhance the core competitiveness of the company's main business products
.
In response to the company's new drug research and development progress, Kunpharm Group stated that at present, the company's self-developed Chinese medicine class 1 new drug KYAZ01-2011-020 suitable for ischemic stroke, suitable for isocitrate dehydrogenase-1 (IDH1) gene Key R&D projects such as KYAH01-2016-079, an innovative class 1 mutation drug, and KYAH02-2016-078, which is suitable for the treatment of autoimmune disease systemic lupus erythematosus (SLE) in cooperation with the Chinese Academy of Chinese Medical Sciences (Tu Youyou team), are progressing as scheduled
.
And in 2021, the company's R&D investment (including capital investment) will total 136 million
.
The company said that it will continue to focus on the research and development field, and will focus its resources on the cardiovascular and cerebrovascular, bone, wind, and kidney areas where the company has advantageous therapeutic areas
.
Regarding the research and development of innovative drugs, Watson Pharma said in the institutional survey that the company is based on differentiated competitive advantages to deploy innovative drug tracks.
Among the company's four existing self-developed projects, there is one global new project, and the rest are cutting-edge projects.
, that is, only 1-2 foreign R&D projects with the same target have entered clinical phase I at most
.
The company's current projects with advanced progress have shown good efficacy data in vivo and in vitro.
It is expected that two projects will enter the IND-ENABLING stage in the second half of this year, and at least 1-2 projects will receive IND approval next year
.
Analysts said that in the future, if the Chinese medicine industry wants to achieve further development, it also needs to rely on research and development innovation
.
The country is constantly optimizing the registration mechanism of proprietary Chinese medicines, and the research and development of traditional Chinese medicines will enter a new era
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
It is predicted that the traditional Chinese medicine market will exceed 1 trillion yuan in 2024, and the market prospect is very impressive
.
Since March 2022, many traditional Chinese medicine companies have also been investigated by institutions
.
For example, Zhenbao Island stated in its investor relations activity record sheet released on March 29 that the company accepted four institutional surveys on March 25, 2022, with the types of institutions being insurance companies, fund companies, and securities companies
.
Kunpharm Group stated in the investor relations activity record sheet released on March 22 that the company received investigations from 22 institutions on March 21, 2022.
The types of institutions are insurance companies, others, fund companies, securities companies, and sunshine private equity institutions.
.
On March 17, Watson Pharmaceuticals released an investor relations activity record sheet, stating that the company received investigations from 6 institutional units on March 17, 2022.
The types of institutions are others, fund companies, securities companies, and sunshine private equity institutions
.
During the survey, issues such as the distribution of innovative Chinese medicines have become one of the topics that institutions are more concerned about
.
So what is the layout and progress of the above-mentioned companies under investigation in innovative traditional Chinese medicine? Among them, Zhenbao Island said in response to the agency's question on "the future layout of innovative traditional Chinese medicine drugs? How will it affect the company?" The company is deploying innovative traditional Chinese medicine products, and it will take time to launch innovative drugs according to the characteristics of different varieties
.
At present, some varieties are immediately undergoing Phase II clinical trials, while others are undergoing pharmaceutical research.
It is expected that they will be approved by the end of next year, and others have already been approved
.
The supplement of other traditional Chinese medicine varieties is also constantly introducing products with clinical and market value, and constantly supplementing short-term products and several large varieties.
Sales are expected this year
.
The research and development and introduction of innovative traditional Chinese medicine drugs will further enhance the core competitiveness of the company's main business products
.
In response to the company's new drug research and development progress, Kunpharm Group stated that at present, the company's self-developed Chinese medicine class 1 new drug KYAZ01-2011-020 suitable for ischemic stroke, suitable for isocitrate dehydrogenase-1 (IDH1) gene Key R&D projects such as KYAH01-2016-079, an innovative class 1 mutation drug, and KYAH02-2016-078, which is suitable for the treatment of autoimmune disease systemic lupus erythematosus (SLE) in cooperation with the Chinese Academy of Chinese Medical Sciences (Tu Youyou team), are progressing as scheduled
.
And in 2021, the company's R&D investment (including capital investment) will total 136 million
.
The company said that it will continue to focus on the research and development field, and will focus its resources on the cardiovascular and cerebrovascular, bone, wind, and kidney areas where the company has advantageous therapeutic areas
.
Regarding the research and development of innovative drugs, Watson Pharma said in the institutional survey that the company is based on differentiated competitive advantages to deploy innovative drug tracks.
Among the company's four existing self-developed projects, there is one global new project, and the rest are cutting-edge projects.
, that is, only 1-2 foreign R&D projects with the same target have entered clinical phase I at most
.
The company's current projects with advanced progress have shown good efficacy data in vivo and in vitro.
It is expected that two projects will enter the IND-ENABLING stage in the second half of this year, and at least 1-2 projects will receive IND approval next year
.
Analysts said that in the future, if the Chinese medicine industry wants to achieve further development, it also needs to rely on research and development innovation
.
The country is constantly optimizing the registration mechanism of proprietary Chinese medicines, and the research and development of traditional Chinese medicines will enter a new era
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
